Temitayo Chidi, MD
Neurology with Special Qualifications in Child Neurology · Sacramento, CANPI 1295992063
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 44.9% of the total.
Across 110 payments — averaging $105.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$5K
- Biomarin Pharmaceutical Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- Jazz Pharmaceuticals Inc.$686
- Idorsia Pharmaceuticals US Inc$619
- SK Life Science, Inc.$340
- plus $2K from 14 others
Across 100 payments — averaging $3071.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$181K
- Jazz Pharmaceuticals Inc.$91K
- SK Life Science, Inc.$31K
- Biohaven Pharmaceutical Holding Company Ltd.$3K
What the payments were for
- Speaking & faculty fees$6,86359%
- Food & beverage$4,56039%
- Education$1321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,554 in reported general payments places this provider in the 80th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 16 | $257 |
| Zolpidem Tartrate | 19 | $31 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Sacramento
- Michael ChezSacramento$374K
- Shailesh AsaikarSacramento$26K
- Allen BottOakland$372K
- Joseph SullivanSan Francisco$240K
- Ann SegerenStanford$172K
- Rajsekar RajaramanLos Angeles$134K
- Deborah HolderLos Angeles$130K
- Akash VirupakshaiahSan Francisco$94K
- Brittany PassiakSan Diego$90K
- Kevin ShapiroMadera$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.